MiNK Therapeutics (INKT) Exchange Rate Effect (2020 - 2026)
MiNK Therapeutics (INKT) posted Exchange Rate Effect of -$1237.0 for Q1 2026, up 94.44% sequentially from -$22249.0 in Q4 2025, and up 32.81% YoY from -$931.42 in Q1 2025.
MiNK Therapeutics (INKT) Exchange Rate Effect (2020 - 2026) Analysis & Trends
MiNK Therapeutics has reported Exchange Rate Effect for 7 years, with the latest figure at -$1237.0 in Q1 2026.
- Quarterly Exchange Rate Effect rose 32.81% year-over-year to -$1237.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$12825.0 (up 69.25% YoY) and the FY2025 annual result came in at -$13429.0, up 75.45% from the prior year.
- Exchange Rate Effect rose to -$1237.0 in Q1 2026 per INKT's latest filing, from -$22249.0 in the prior quarter.
- Over five years, Exchange Rate Effect peaked at $35387.0 in Q4 2022 and troughed at -$29340.0 in Q1 2023.
- A 5-year average of -$4425.3 and a median of -$4586.0 in 2022 frame the typical range for Exchange Rate Effect.
- The sharpest annual moves came in 2022 and 2024: Exchange Rate Effect soared 236.54% in 2022, then plunged 646.04% in 2024.
- Over 5 years, Exchange Rate Effect stood at $35387.0 in 2022, then plunged by 87.82% to $4309.0 in 2023, then slumped by 646.04% to -$23529.0 in 2024, then grew by 5.44% to -$22249.0 in 2025, then surged by 94.44% to -$1237.0 in 2026.
- According to Business Quant data, Exchange Rate Effect over the past three periods registered -$1237.0, -$22249.0, and -$5033.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.57 Bn | 131.72 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 65.44 Bn | 60.25 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.06 Bn | 54.93 Bn | 52.00 Mn | -2.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 19.84 Mn |
| 6 | Alnylam Pharmaceuticals | 31.89 Bn | 28.58 Bn | 992.69 Mn | -2.45 Mn |
| 7 | BioNTech SE | 28.11 Bn | 9.72 Bn | 668.28 Mn | 1.63 Mn |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | -287,000.00 |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | - |
| 10 | MiNK Therapeutics | 60.23 Mn | 60.23 Mn | - | -2,041.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2,041.00 |
| Jun 30, 2026 | -2,041.00 |
| Mar 31, 2026 | -1,237.00 |
| Mar 31, 2026 | -1,237.00 |
| Dec 31, 2025 | -22,249.00 |
| Dec 31, 2025 | -22,249.00 |
| Sep 30, 2025 | -5,033.00 |
| Sep 30, 2025 | -5,033.00 |
| Jun 30, 2025 | 15,694.00 |
| Jun 30, 2025 | 15,694.00 |
| Mar 31, 2025 | -1,841.00 |
| Mar 31, 2025 | -1,841.00 |
| Dec 31, 2024 | -23,529.00 |
| Dec 31, 2024 | -23,529.00 |
| Sep 30, 2024 | 2,688.00 |
| Sep 30, 2024 | 2,688.00 |
| Jun 30, 2024 | -19,020.00 |
| Jun 30, 2024 | -19,020.00 |
| Mar 31, 2024 | -14,838.00 |
| Mar 31, 2024 | -14,838.00 |